Bayer Hires US Lobby Firm on Drug Issues

Germany’s Bayer has hired US lobby firm Williams & Jensen to aid its campaign for continued access to contraceptives.

The move follows June’s decision by the US Supreme Court to overturn Roe v. Wade, the legislative template set by an earlier iteration of the court that guaranteed a woman’s right to terminate a pregnancy.

The legislation’s overturn has led to a flurry of state-level initiatives to block access to birth control as well as abortion. Since its 2006 acquisition of German women’s health specialist Schering, Bayer has become a major player in this market and has significant interests to defend.

Under the trade names Mirena, Skyla and Kyleena, Bayer’s pharmaceuticals division produces three of the international top-selling intrauterine devices (IUDs) 

The Leverkusen-based player is currently building new state-of- the art production lines for hormonal implants and hormonal intrauterine systems at Alajuela, Costa Rica, and Turku, Finland, to secure long-term supply to meet increased global demand for long-acting reversible contraceptives (LARCs), The  loss of the vast US market would be a decisive blow.

Bayer is also planning a state-of-the-art plant in Costa Rica that will focus on long-acting reversible contraception, including contraceptive implants and IUDs.  Start-up is scheduled for 2024.

The current state of play on access to contraceptives in a number of US states as murky. In July, a Democratic bill passed by the House of Representatives to codify the right to birth control in law, failed in the Senate due to opposition by Republicans. The administration of president Joe Biden subsequently reminded health insurers that federal laws require them to cover all forms of birth control approved by the US Food and Drug Administration (FDA) with no co-pays.

Bayer research scientist from the Pharmaceuticals Division in a Berlin...
Bayer research scientist from the Pharmaceuticals Division in a Berlin laboratory. © Bayer

Drugmakers alarmed over Medicare negotiation right

Beyond birth control, Williams & Jensen also will work on Bayer’s behalf on issues related to drug pricing. The US pharmaceutical industry has voiced opposition to a provision of the Biden administration’s Inflation Reduction Act, which gives Medicare, the national insurance program for the elderly, the right to negotiate prices for some prescription drugs.

The freshly passed price negotiation right will take effect after the US Department of Health and Human Services publishes guidelines on the new rules. Several pharmaceutical companies are believed to poised to sue.

Trade groups such as the Pharmaceutical Research and Manufacturers of America (PhRMA) have voiced criticism. Speaking to US media, PhRMA president and CEO Stephen Ub called the Senate’s decision a “tragic loss for patients” based on a “litany of false promises.”

Author: Dede Williams, Freelance Journalist

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.